DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Eculizumab is an investigational drug.
There have been 67 clinical trials for Eculizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2012.
The most common disease conditions in clinical trials are Hemoglobinuria, Paroxysmal, Hemoglobinuria, and Syndrome. The leading clinical trial sponsors are Alexion Pharmaceuticals, National Heart, Lung, and Blood Institute (NHLBI), and Mario Negri Institute for Pharmacological Research.
There are seventy-one US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Eculizumab
|The Use of Eculizumab in HELLP Syndrome||Johns Hopkins University||Phase 1|
|Eculizumab to Cemdisiran Switch in aHUS||Alnylam Pharmaceuticals||Phase 2|
|Eculizumab to Cemdisiran Switch in aHUS||Mario Negri Institute for Pharmacological Research||Phase 2|
Top disease conditions for Eculizumab
Top clinical trial sponsors for Eculizumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Eculizumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Eculizumab||Start Trial||Oncolytic virus adjunct therapy with agents that increase virus infectivity||Genelux Corporation (San Diego, CA)||Start Trial|
|Eculizumab||Start Trial||Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis||Alexion Pharmaceuticals, Inc. (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|